New York Presbyterian released the following update about a phase 2 trial combining Nivolumab (a.k.a Opdivo, anti-PD-1) and Ipilimumab (a.k.a Yervoy, anti-CTLA-4):
Results were presented at ASCO2017:
http://abstracts.asco.org/199/AbstView_199_184079.html
Apparently, there was no response observed in synovial sarcoma patients (only a few patients participated):